Rapport Therapeutics (RAPP) Expected to Announce Earnings on Thursday

Key Points

• Rapport Therapeutics is set to announce its Q2 2025 earnings on August 14th, expected to report a loss of ($0.87) per share for the quarter.
• Following a previous quarterly earnings report that exceeded estimates, analysts project a total loss of ($4) EPS for the current fiscal year, with ongoing predictions placed at ($3) EPS for the next fiscal year.
• JMP Securities maintains a "market outperform" rating for RAPP with a price target of $28.00, while HC Wainwright sets a buy rating and price objective at $31.00.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Thursday, August 14th. Analysts expect Rapport Therapeutics to post earnings of ($0.87) per share for the quarter.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.09. On average, analysts expect Rapport Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Rapport Therapeutics Price Performance

Rapport Therapeutics stock opened at $14.61 on Thursday. Rapport Therapeutics has a 1 year low of $6.43 and a 1 year high of $29.74. The firm's 50 day moving average price is $12.95 and its 200-day moving average price is $11.94. The stock has a market cap of $533.27 million, a P/E ratio of -4.23 and a beta of 0.62.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on RAPP shares. JMP Securities reiterated a "market outperform" rating and issued a $28.00 price target on shares of Rapport Therapeutics in a report on Tuesday, July 8th. HC Wainwright initiated coverage on Rapport Therapeutics in a research report on Wednesday. They set a "buy" rating and a $31.00 price objective for the company.

Insider Activity at Rapport Therapeutics

In related news, insider David Bredt sold 8,500 shares of the firm's stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $14.00, for a total value of $119,000.00. Following the completion of the transaction, the insider directly owned 435,142 shares of the company's stock, valued at approximately $6,091,988. This trade represents a 1.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Hedge Funds Weigh In On Rapport Therapeutics

Several institutional investors have recently bought and sold shares of RAPP. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC bought a new stake in Rapport Therapeutics during the first quarter worth approximately $2,039,000. Rhumbline Advisers boosted its holdings in shares of Rapport Therapeutics by 40.1% in the 1st quarter. Rhumbline Advisers now owns 14,358 shares of the company's stock worth $144,000 after purchasing an additional 4,109 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Rapport Therapeutics by 86.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company's stock valued at $99,000 after purchasing an additional 4,582 shares during the last quarter.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.